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Serum antinuclear antibodies (ANA) are occasionally noted in the patients with 
non-alcoholic steatohepatitis (NASH). We examined the significance of ANA in NASH by 
comparing the clinicopathological features in the patients with ANA-positive NASH 
(n=35) and ANA-negative NASH (n=36). Inflammatory cell profiles and the distribution of 
oxidative stress markers were also examined immunohistochemically. The ANA-positive 
NASH was significantly associated with female gender (p= .005), high degree of portal 
inflammation (p= .039), interface activity (p= .036) and hepatocellular ballooning 
(p= .0008). In addition, The ANA of high-titer (320-fold or more) was significantly 
associated with the histological grade and stage of NASH (p= .02). The degree of steatosis 
is rather mild in high-titer ANA group (p= .01). The analysis of inflammatory cell profiles 
revealed that CD3-positive T cells were predominant and plasma cells were rather few in 
portal area and hepatic lobules in both ANA-positive and ANA-negative groups. There was 
no difference in the distribution of oxidative stress markers between ANA-positive and 
ANA-negative groups. These findings suggest that the presence of ANA may be related to 
the progression of NASH and that a different type of autoimmune mechanisms may be 
involved in the pathogenesis of NASH with ANA, compared to the pathogenesis of 
autoimmune hepatitis. 
 





Nonalcoholic fatty liver disease (NAFLD) becomes a recognized clinical entity, associated 
with obesity, diabetes mellitus and other excess nutrition uptake1. Nonalcoholic 
steatohepatitis (NASH) is a part of NAFLD and characterized by histological features 
resembling alcoholic hepatitis such as steatosis, hepatocellular ballooning, neutrophilic 
infiltration and fibrosis 2, 3. Recently, NASH is recognized as a cause of cryptogenic 
cirrhosis and hepatocellular carcinoma 4,5. The pathogenesis of NASH is multifactorial and 
the two hits theory is well known 6, which accounts for accumulation of fat as the first hit 
and hepatocellular injury in fatty liver as the second hit. The oxidative stress, ATP 
depletion and mitochondrial dysfunction as second hits are suggested to play an important 
role in hepatocellular injury for the progression of steatohepatits1. Insulin resistance is also 
germane to NASH.  
In patients with non-alcoholic fatty liver disease (NAFLD), the presence of 
autoantibodies, especially antinuclear antibodies (ANA), is noted occasionally. The 
prevalence of ANA in patients with NAFLD is reportedly higher than the general 
population, ranging from 12% to 46% 4, 7-11. Since ANA is a characteristic parameter in 
autoimmune hepatitis (AIH), it is critical to differentiate NAFLD with ANA and AIH. 
There have been several reports about the significance of ANA in NAFLD patient 1, 8,9, 13-16, 
but it remains controversial 1,16. For example, Adams et al. reported that the positive 
autoantibodies were associated with higher fibrosis stage, higher inflammatory grade and 
higher levels of gammaglobulin 8. In contrast, Cotler et al. reported that ANA in the 
patients with NASH was not associated with the degree of inflammation, and that it was 
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nonspecific antibody response 13. 
In this study, we examined the clinicopathological significance of ANA in NASH, 
comparing ANA positive cases and ANA negative cases. We put a special emphasis on the 
histopathological features, the inflammatory cell profile and the distribution of oxidative 
stress marker. 
 
Materials and Methods 
Subjects 
The study included 35 patients with ANA-positive NASH and 36 with ANA-negative 
NASH. Although there are many women in the general population who are positive for 
ANA and low-titer  (40-fold) of ANA may be less important in general clinical practice, 
we regarded ANA-positive when the titer of ANA was 40-fold or more according to the 
AIH scoring system in which 40-fold of ANA is scored as +1. When the titer of ANA was 
320-fold or more, ANA was regarded as high-titer. All of these cases were collected from 
the files of the Department of Human Pathology, Kanazawa University Graduate School of 
Medicine and affiliated hospitals between 1996 and 2006. All patients were negative for 
hepatitis viral markers, and there was no history of alcohol abuse. All patients underwent 
clinical and laboratory evaluation, including AST, ALT, ALP, γ-GTP and IgG. The 
diagnosis as NASH was made based on clinical data and pathologic findings of liver biopsy. 
The patients were classified using AIH scoring system reported by the International 
Autoimmune Hepatitis Group17. The patients with NASH who could be classified as 




Liver Biopsy and histopathological evaluation 
One specimen was a wedge biopsy material and the remainings were needle biopsies. Liver 
biopsy material were fixed in neutral formalin, embedded in paraffin and cut into 4 μm 
sections. Several of them were stained with hematoxylin and eosin and silver reticulin stain. 
Two liver pathologists examined specimens, who were blind to the titer of ANA. The grade 
and stage of NASH were evaluated according to the classification of Brunt et al 2. The 
degree of steatosis was subclassified as 0, <5%; 1, 5-33%; 2, 33-66%; 3, >66%. The degree 
of portal inflammation and hepatocellular ballooning was subclassified as 1, mild; 2, 
moderate; 3, severe. The presence of Mallory body and/or cytoplasmic coagulum was also 
evaluated with the aid of immunostaining for cytokeratin (CK) 8. The degree of interface 
activity was evaluated as follows: 0, none; 1, minimal; 2, mild; 3, moderate to severe.  
 
Immunohistochemistry 
For the assessment of inflammatory cell profile and for the detection of oxidative stress 
marker, immunohistochemical staining was performed as described previously18 using a 
Ventana automated stainer (Ventana medical systems, Tucson, AZ, USA). Primary 
antibodies included CD3 (mouse monoclonal (mono); no dilution; Ventana, Tucson, AZ, 
USA), CD8 (mono, 1/50, Ventana), CD20 (mono, no dilution, Ventana), CD138 (mono; 
1/50; Dako, Glostrup, Denmark), myeloperoxidase (MPO)(rabbit polyclonal; 1/50; Dako), 
CK8 (mono; 1/50; Dako), 4-hydroxy-2'-nonenal (4-HNE)(mono; 1/20; Japanese Aging 
Control Institute (JAICA)), 4-hydroxy-2-hexenal (4-HHE)(mono; JAICA; 1/500) and 
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8-hydroxydeoxyguanosine (8-OHdG) (mono; JAICA; 1/100). Immunostaining for 
8-hydroxydeoxyguanosine (8-OHdG) was performed using Ventana Alkaline Phosphatase 
Enhanced Detection kit and Ventana Basic DAB Detection kit was used with other 
antibodies. Negative controls included substituting the primary antibody with similarly 
diluted normal mouse or rabbit immunoglobulin.  
Inflammatory cell profile 
Inflammatory cells positive for CD3 (a marker for T cell), CD8 (cytotoxic/suppressor T 
cell), CD20 (B cell), CD138 (plasma cell) and myeloperoxidase (MPO) (neutrophil and 
macrophage) were evaluated in 15 liver specimens of ANA-positive NASH and 15 of 
ANA-negative NASH. CD8-posiive cells were also assessed in 8 of ANA-positive NASH 
and 8 of ANA-negative NASH. CD3, CD8, CD20, CD138 and MPO positive cells were 
counted in 2 and 10 different high power fields (HPF, 10x eyepiece and 40x lens) in the 
portal area and the hepatic lobule, respectively. Since CD3-positive T cells were 
predominantly seen in preliminary study, the ratio of CD8 /CD3, CD20/CD3, CD138/CD3 
and MPO/CD3 positive cells were evaluated to assess the inflammatory cell profiles in 
ANA-positive and ANA-negative NASH. In addition, we examined 10 specimens taken 
from the patients with definite AIH for comparison. 
Oxidative stress marker 
4-hydroxy-2'-nonenal (4-HNE), 8-hydroxydeoxyguanosine (8-OHdG) and 4-hydroxy- 
2-hexenal (4-HHE) were evaluated as oxidative stress markers19-21. Four histological 
normal livers were also examined as controls. In normal liver samples, there were no 
positive signals of 8-OHdG, 4-HNE and HHE. For semi-quantitative assessment, 8-OHdG 
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or 4-HNE positive hepatocytes were counted at 10 different high power fields (HPF, 10x 
eyepiece and 40x lens). At least 1000 hepatocytes were examined and the positive rate was 
expressed as % of hepatocytes. The degree of 4-HHE immunohistochemical staining was 
evaluated as follows: 0; negative, 1; slightly positive, 2; mildly～moderately positive, 3; 
strongly positive.  
 
Statistics 
Data are expressed as the mean ± SD. Statistical analysis was performed using 
Mann-Whitney's U test. When p value was less than 0.05, the difference was regarded as 
statistically significant.  
 
Results 
Clinical Features in ANA-positive and ANA-negative NASH 
The clinical features and laboratory data are summarized in Table 1. The titer of ANA was 
ranged 40 to 5120-fold in ANA-positive group (40-fold, n=11; 80-fold, n= 3; 160-fold, n= 
10; 320-fold, n=2; 640-fold, n=5; 1280-fold, n= 3; 5120-fold, n= 1). Fourteen and one 
patients had an AIH score of 10-15 and belonged to probable cases before biopsy in 
ANA-positive and ANA-negative groups, respectively17 Female patients were significantly 
predominant in ANA-positive group, when compared with ANA-negative group (p=0.005). 
There was no difference in age, the prevalence of obesity, diabetes mellitus and 
hyperlipidemia between the ANA-positive and ANA-negative groups. In laboratory data, 
the level of AST in high-titer (320-fold or more) ANA-positive group was significantly 
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high, when compared with the ANA-negative group.  
 
Histological Features in ANA-positive and ANA-negative NASH 
The histological features are summarized in Table 3. Figure 1 showed the example of 
histopathological findings in ANA-positive and ANA-negative NASH. When 
ANA-positive NASH and ANA-negative NASH were compared, the degree of hepatocytes 
ballooning (p=0.0008), portal inflammation (p=0.039) and interface activity (p=0.036) were 
significantly high in ANA-positive patients. However, portal inflammation and interface 
activity was rather mild in ANA-positive NASH, when compared with typical AIH. Lymph 
follicle formation was not seen and plasma cell infiltration was not evident in ANA-positive 
and ANA-negative NASH. When histological features were included in AIH scoring 
system17 after liver biopsy, 4 patients had AIH score of 10 or 11 in ANA-positive group. 
Although grade of NASH tended to be higher in ANA-positive patients, there were no 
significant differences. When the patients with NASH with high-titer ANA were compared 
with ANA-negative NASH patients, histological grade (p=0.02) and stage of NASH 
(p=0.02), portal inflammation (p=0.006), interface activity (p=0.0001) and hepatocellular 
ballooning (p=0.03) were significantly high in high-titer ANA with NASH. The degree of 
steatosis was rather low in high-titer ANA-positive NASH, when compared with 
ANA-negative NASH (p=0.02). There was no significant difference in the degree of 
lobular inflammation and the presence of cytoplasmic coagulum between high-titer 




Inflammatory cell profiles in ANA-positive and ANA-negative NASH 
The inflammatory cell profile in portal area and hepatic lobules is summarized in Table 3 
and 4, respectively. CD3 positive T cells were predominant in portal area and hepatic 
lobules in both of ANA-positive and ANA-negative NASH (Fig.2). CD8-positive cells are 
about a half of CD3-positive cells in number. CD3 and CD8-positive cells were seen at the 
interface of portal area and hepatic lobules. CD138-positive plasma cells and MPO-positive 
neutrophils/macrophages were occasionally seen in portal area and hepatic lobules. There 
were no significant differences in the inflammatory cell profiles in portal tracts and hepatic 
lobule between ANA-positive and ANA-negative patients. CD20/ CD3 and CD138/CD3 
ratios were significantly low in portal area in ANA-positive and ANA-negative NASH, 
when compared with those in AIH (p<0.05). CD8/ CD3 ratio was rather high in portal area 
in ANA-negative NASH, when compared with those in AIH (p<0.05) (table 3). MPO/CD3 
ratio was significantly high in hepatic lobules in ANA-positive and ANA-negative NASH, 
when compared with those in AIH (p<0.05). Whereas, CD138/CD3 ratio was significantly 
low in hepatic lobules in ANA-positive and ANA-negative NASH compared with those in 
AIH (p<0.05) (table 4). 
 
Oxidative stress markers in ANA-positive and ANA-negative NASH 
The distribution of oxidative stress markers is summarized in Table 6. In accordance with 
previous reports21-23, the expression of 8-OHdG was detected in the nuclei of hepatocytes, 
sinusoidal cells and some inflammatory cells (Fig 3). 8-OHdG was rather predominantly 
seen in hepatocytes in the centrilobular area. 4-HNE was detected in the granules in the 
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cytoplasm of hepatocytes (Fig 3) and 4-HHE was detected diffusely in the cytoplasm of 
hepatocytes to various degrees. There were no significant differences between 
ANA-positive and ANA-negative NASH in the distribution of 8-OHdG and 4-HNE. 
 
Discussion 
ANA is occasionally detected in patients with NASH and its significance of ANA remains 
controversial, so far 1,4,7-16. To address this issue, we compared clinical and pathological 
features in the patients with ANA-positive and ANA-negative NASH in this study. In the 
present study, ANA-positive NASH was associated with female gender. This female 
predominance agreed with the previous study reported by Cotler et al.13 The patients were 
rather old and the prevalence of obesity, diabetes mellitus and hyperlipidemia were slightly 
higher in ANA-positive NASH, but the difference was not significant. There have been no 
previous studies reporting the association of these factors with ANA-positive NASH.  
Regarding insulin resistance, Loria et al. reported that high-titer ANA was associated with 
insulin resistance 9, whereas Adams et al. reported that it was neither associated with higher 
fasting insulin levels or insulin resistance11. Since the present study is retrospective one, 
details clinical data regarding insulin resistance was not available.  
The detail histological evaluation in the present study revealed that ANA-positive 
NASH was significantly associated with high degree of portal inflammation, interface 
activity and hepatocellular ballooning. Furthermore, it is of interest that ANA of high-titer 
(320-fold or more) with NASH was significantly associated with the histological grade and 
stage of NASH, the degree of portal inflammation and interface activity. The degree of 
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steatosis is rather mild in high-titer ANA group. The findings in the present study support 
the previous study8 reporting the association of ANA in NASH with higher fibrotic stage 
and necroinflammatory grade. Taken them into consideration, it is plausible that the 
high-titer of ANA may be related to the progression of NASH. There have been no reports 
describing the higher degree of hepatocellular ballooning in ANA-positive patients, so far. 
The present study reported firstly the association of hepatocellular ballooning with the 
presence of ANA.  
Although the combination of ANA-positive, high degree of portal inflammation and 
interface activity may suggest autoimmune features, the overlap of AIH appears to be 
unlikely in our ANA-positive NASH. Portal inflammation and interface activity were rather 
mild, when present, compared to typical AIH. Lymph follicle formation and plasma cell 
infiltration were not evident and the findings were insufficient to make a diagnosis as AIH. 
When histological features were included in AIH scoring system17 after liver biopsy, 4 
patients had AIH score of 10 or 11 in ANA-positive group. The inflammatory cell profiles 
revealed that the infiltration of CD3-positive T cells was predominant in portal area. It is of 
interest that CD20/ CD3 and CD138/CD3 ratios were significantly low in portal area in 
ANA-positive and ANA-negative NASH, when compared with those in AIH. MPO/CD3 
ratio was significantly high in hepatic lobules in ANA-positive and ANA-negative NASH, 
when compared with those in AIH. Whereas, CD138/CD3 ratio was significantly low in 
hepatic lobules in ANA-positive and ANA-negative NASH compared with those in AIH. 
These data clearly exclude the possible overlap of AIH, irrespective of rather high degree of 
portal inflammation and interface activity in ANA-positive NASH. Furthermore, these 
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differences of inflammatory cell profiles between ANA-positive NASH and AIH suggest 
that a different type of autoimmune mechanisms may be involved in the pathogenesis of 
ANA-positive NASH and related to the progression of NASH.  
Recently, Albano et al.24 reported that circulating IgG against lipid peroxidation 
products including malondialdehyde (MDA) was significantly higher in NAFLD patients 
than in controls. Oxidative stress-dependent immune responses were not associated with 
obesity, type 2 diabetes, or with serum cholesterol, ferritin, or aminotransferase levels24. 
Titers of lipid peroxidation related antibodies were also independent of the extent of 
steatosis and were similarly distributed in patients with and without necroinflammation24. 
In contrast, lipid peroxidation related antibodies were significantly increased in patients 
with advanced fibrosis or cirrhosis 24. These results indicate that the presence of immune 
reactions triggered by oxidative stress can be an independent predictor of progression of 
NAFLD to advanced fibrosis24. In the present study, the oxidative stress markers (8-OHdG，
4-HNE and 4-HHE) were frequently detected in both ANA-positive and ANA-negative 
cases, suggesting the oxidative stress was involved in the pathogenesis of NASH. Since 
histological grade and stage of NASH was high in high-titer ANA-positive NASH group in 
this study, immune response towards lipid peroxidation in the patients with NAFLD might 
be related to the generation of autoantibodies. Further analysis is demanded to clarify this 
point. 
Similarly to NAFLD, the presence of non-organ specific antibodies (NOSAs) 
including ANA has been reported in HCV-related chronic liver disease25-27. The association 
between the presence of NOSAs and the clinical, biochemical, and histological picture of 
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HCV related chronic liver disease is still controversial25,26. Several studies reported a higher 
biochemical and histological activity in patients with autoantibodies and with HCV related 
chronic liver disease25,26. Interestingly, the presence of autoantibodies correlated with the 
activity of liver disease, suggesting a hypothetical role in the progression of liver damage 
25,26. Furthermore, a study reported that ANA-positive chronic hepatitis C showed poorer 
response to IFN therapy29. In contrast, other reports have failed to identify the presence of 
NOSAs as an untoward factor for chronic liver disease27, 28. Autoantibodies in the patients 
with HCV-related chronic liver disease may reflect autoimmune reactions associated with 
viral infection24 as described in various viral disorders 30-32. Alternatively, positive ANA 
might be associated with the progression of chronic liver disease in viral hepatitis and 
NASH in common.  
In summary, the patients with ANA-positive NASH were characterized by female 
predominance, higher degree of portal inflammation, interface activity and hepatocellular 
ballooning. In addition, high-titer ANA was associated with the higher grade and stage of 
NASH. Inflammatory cell profile in ANA-positive NASH was different from a typical AIH. 
These findings suggest that the presence of ANA may be related to the progression of 
NASH and that a different type of autoimmune mechanisms may be involved in the 
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Fig 1. A) and B) Histopathological findings of ANA-positive NASH. A) Lymphocytic 
infiltration was seen in the portal tract and fibrous septa. Steatosis was seen in hepatic 
parenchyma. B) Arrows indicate the lymphocytic infiltration at the edge of the portal tract 
(interface activity). This specimen was scored as portal inflammation, 3 and interface 
activity, 2.  Hepatocellular ballooning was also seen (arrowheads). 
C) and D) Histopathological findings of ANA-positive NASH. C) Lymphocytic infiltration 
was seen in the portal tract and fibrous septa. Steatosis was seen in hepatic parenchyma. D) 
There were few lymphocytes in portal tracts. P, portal tract. Hematoxylin and eosin, A and 
C, x200; B and D, x400 (original magnification) 
  
Fig 2. Inflammatory cell profile in portal area of ANA-positive NASH. A) CD3-positive 
cells were predominant in the portal tract. Immunostaining for CD3 and hematoxylin. B) 
CD8-positive cells were about a half of CD3-positive cells in the portal tracts. 
Immunostaining for CD8 and hematoxylin. C) Compared with T cells, CD20-positive T 
cells were rather small in number. Immunostaining for CD20 and hematoxylin. D) There 
were few CD138-positive plasma cells in portal tracts. Immunostaining for CD138 and 
hematoxylin. P, portal tract. A-D, x400 (original magnification) 
 
Fig 3. The expression of oxidative stress markers. A) 8-OHdG was detected in the nuclei of 
hepatocytes (arrows). Immunostaining for CD138 and hematoxylin. B) 4-HNE was 
detected in granules in the cytoplasm of hepatocytes. Immunostaining for 4-HNE and 
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hematoxylin. (c) HHE was detected in fine vesicles in the cytoplasm of hepatocytes. 
Immunostaining for HHE and hematoxylin. A-C, x400 (original magnification). 
 
Table 1   Clinical features in the patients with non-alcoholic steatohepatitis with and without serum antinuclear antibody 
ANA-negative NASH ANA-positive NASH High-titer ANA NASH   
  (n=36) (n=35) p value* (n=11) p value* 
Female (%) 18 (50.0%) 28 (80%) 0.002 10 (92%) 0.02 
Age (mean±SD, range) 50 ±17.7 (14-84) 57±13.9 (24-80) 0.23 62 ± 8.1 (51-80) 0.07 
Obesity (%) 14 (41%) 19 (54%) 0.20 5 (45%) 0.70 
Diabetes mellitus (%) 8 (22%) 10 (28%) 0.54 4 (36%) 0.35 
Hyperlipidemia (%) 5 (14%) 11 (31%) 0.08 3 (27%) 0.93 
      
AST (U/L) (mean±SD, range) 81±40.0 (14-193) 106 ±90.2 (29-532) 0.20 104 ± 48.2 (56-177) 0.15 
ALT (U/L) (mean±SD, range) 114 ±73.7 (23-312) 142±104.1 (27-524) 0.26 136 ± 75.4 (25-282) 0.24 
ALP (U/L) (mean±SD, range) 302 ±107.4 (133-529) 300±123.8 (71-636) 0.95 278 ± 71.8 (217-436) 0.58 
γ-GTP (U/L) (mean±SD, range) 187± 402.3 (14-2110) 124±141.1 (38-650) 0.72 78.5 ± 51.1 (52-153) 0.83 
IgG (mg/dl) 1387.7 ± 354.9 1426.3 ± 397.5 0.79 1766.43 ± 471.5 0.053 
      
AIH score <10 32 (97%) 16 (53%) 0.0000005 3 (33%) 0.00003 
                  10-15 (Probable AIH) 1 (3%) 14 (47%)  6 (67%)  
                  15< (Definite AIH) 0 0  0  
ANA, antinuclear antibodies; NASH, non-alcoholic steatohepatitis; *, p value versus ANA-negative NASH







(n=35) p value* 
High-titer ANA 
NASH 
(n = 11) p value* 
Grade 1 18 (50%) 11 (31%) 0.054 2 (18%) 0.02 
 2 17 (47%) 19 (54%)  6 (55%)  
 3 1 (3%) 5 (15%)  3 (27%)  
       
   
   
   
Stage 1 17 (47%) 15 (43%) 0.46 1 (9%) 0.009 
 2 11 (31%) 8 (23%)  3 (27%)  
 3 7 (19%) 11 (31%)  7 (64%)  
 4 1 (3%) 1 (3%)  0   
    
Portal inflammation 1 22 (61%) 14 (40%) 0.039 1 (9%) 0.001 
 2 9 (25%) 9 (26%)  4 (36%)  
 3 5 (14%) 12 (34%)  6 (55%)  
    
Interface activity 0 22 (61%) 15 (43%) 0.036 0  0.00005 
 1 10 (27%) 6 (17%)  3 (27%)  
 2 2 (6%) 10 (29%)  6 (55%)  
 3 2 (6%) 4 (11%)   2 (18%)  
       
Lobular inflammation 1 19 (53%) 21 (60%) 0.74 6 (55%) 0.63 
 2 15 (41%) 10 (29%)  2 (18%)  
 3 2 (6%) 4 (11%)  3 (27%)  
    
  (Cont’d)       
       
Steatosis 1 17 (47%) 21 (60%)  0.33 10 (91%) 0.01 
 2 10 (27%) 7 (20%)  1 (9%)  
 3 9 (25%) 7 (20%)  0  
       
Hepatocellular ballooning 1 17 (47%) 6 (17%) 0.0008 2 (18%) 0.06 
 2 11 (31%) 8 (23%)  4 (36%)  
 3 8 (22%) 21 (60%)  5 (45%)  
       
Mallory body (%)  10 (28%) 15 (43%) 0.28 6 (55%) 0.10 
       
Cytoplasmic coagulum (%)  21 (58%) 24 (69%) 0.37 8 (73%) 0.39 
ANA, antinuclear antibodies; NASH, non-alcoholic steatohepatitis; High-titer ANA, the titer of ANA was 320-fold or more; *, p value 
versus ANA-negative NASH;  
 Table 3 Inflammatory cell profiles in portal area in the patients with NASH with and without serum antinuclear antibody 
  
ANA negative NASH 
n=8 
ANA positive NASH  
n=8 p value* 
AIH 
n=10 
CD20/CD3 (ratio) 0.16 ± 0.11a 0.17 ± 0.10a 0.83 0.34±0.17 
CD8/CD3 (ratio) 0.61 ± 0.07b 0.56 ± 0/12 0.37 0.46±0.10 
CD138/CD3 (ratio) 0.06 ± 0.06b 0.05 ± 0.06b 0.83 0.26±0.06 
ANA, antinuclear antibodies; NASH, non-alcoholic steatohepatitis; *, p value versus ANA-negative NASH; a, p<0.05 vs AIH; b, p<0.01 
vs AIH 
Table 4 Inflammatory cell profiles in hepatic lobules in the patients with NASH with and without serum antinuclear antibody  
  
ANA positive NASH  
n=15 
ANA negative NASH 
n=15 p value* 
AIH 
n=10 
CD20/CD3 (ratio) 0.097 ± 0.06 0.097 ± 0.04 0.83 0.10 ± 0.07 
CD8/CD3 (ratio) 0.60 ± 0.11 0.55 ± 0.07 0.14 0.54 ± 0.07 
MPO/CD3 (ratio) 0.19 ± 0.12a 0.16 ± 0.08 a 0.43 0.01 ± 0.02 
CD138/CD3 (ratio) 0.013 ± 0.015 a 0.018 ± 0.018 a 0.45 0.17 ± 0.08 
ANA, antinuclear antibodies; NASH, non-alcoholic steatohepatitis; *, p value versus ANA-negative NASH; a, p<0.01 vs AIH
Table 5  Semi-quantitative assessment of 8-OHdG, 4-HNE and 4-HHE in the patients with NASH  





ANA negative NASH 
 
ANA positive NASH 
 p value 
8-OHdG positive rate (%)  39.7 ± 31.0 30.2 ± 25.0 0.17 
     
4-HNE positive rate (%)  20.1 ± 14.8 20.2 ±13.8 0.99 
     
4-HHE  0 7 8 0.94 
 1 11 7  
 2 4 4  
 3 4 5  
ANA, antinuclear antibodies; NASH, non-alcoholic steatohepatitis; 8-OHdG, 8-hydroxydeoxyguanosine; 4-HNE, 4-hydroxy-2'-nonenal;  
4-HHE, 4-hydroxy- 2-hexenal. 



